Iambic Therapeutics, Inc.
Iambic Therapeutics is a biotechnology company based in San Diego, California. It develops small molecule therapeutics using artificial intelligence platforms that support drug discovery and candidate design. Its technologies include Enchant and NeuralPLexer. The company's drug candidates include IAM-1363, a selective HER2 inhibitor; IAM-K1 and IAM217, which inhibit KIF18A; and IAM-C1, a CDK2/4 inhibitor.
Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.
Jefferies initiated coverage on Iambic Therapeutics (NASDAQ:IAM) with a buy rating and $35.00 price target, citing its AI platform's potential. The firm highlighted early data for IAM1363 and modeled peak sales for its pipeline. The stock is up from $10.17 to $13.38 but below its 52-week high. BofA Securities also initiated coverage with a buy rating and $30.00 target, praising its AI-driven drug discovery.
BofA Securities initiated coverage on Iambic Therapeutics (NASDAQ:IAM) with a buy rating and a $30.00 price target, citing its AI-driven drug design. The firm highlighted the company's unique approach and potential for cost reduction and faster development. IAM's stock is currently trading at $10.17, with a market cap of $482 million. InvestingPro data suggests the stock may be overvalued.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning IAM (Iambic Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent IAM coverage spans financial news, ipo and technology.
In the last 30 days, IAM insiders filed 1 SEC Form 4 transaction — 1 purchase ($11.5M) and no sales. The most active reporter was Rachlin Evan Lockwood with 1 filing.
Analyst upgrade with a high price target suggests strong upside potential.
Analyst upgrade and price target raise likely support upside momentum.
Analyst initiation and buy rating are likely to drive buying interest.
Positive early‑stage trial results could boost investor sentiment and drive short‑term price appreciation, though data are still early and risk remains.
Insider purchase signals confidence from a board member, likely supporting short-term price stability or modest upside.
AlphAI scores every news story that mentions IAM with an AI model for sentiment and relevance, and aggregates insider trades from Iambic Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.
Jefferies initiated coverage on Iambic Therapeutics (NASDAQ:IAM) with a buy rating and $35.00 price target, citing its AI platform's potential. The firm highlighted early data for IAM1363 and modeled peak sales for its pipeline. The stock is up from $10.17 to $13.38 but below its 52-week high. BofA Securities also initiated coverage with a buy rating and $30.00 target, praising its AI-driven drug discovery.
BofA Securities initiated coverage on Iambic Therapeutics (NASDAQ:IAM) with a buy rating and a $30.00 price target, citing its AI-driven drug design. The firm highlighted the company's unique approach and potential for cost reduction and faster development. IAM's stock is currently trading at $10.17, with a market cap of $482 million. InvestingPro data suggests the stock may be overvalued.
Iambic Therapeutics (IAM) shared updated Phase 1/1b trial data for IAM1363, showing anti-tumor activity, intracranial responses, and favorable tolerability in HER2-altered cancers. The results build on prior 2025 ESMO data, according to the company.
Rachlin Evan Lockwood purchased 718,750 indirectly-held shares of Iambic Therapeutics, Inc. (IAM) at $16.00 ($11.50M total) on 2026-10-16.
UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.
Iambic Therapeutics, Inc. (IAM) filed an SEC Form 8-K — Regulation FD Disclosure. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 16, 2026, Iambic Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of D
The IPO market saw few listings, with biotech companies City Therapeutics (CTY) and Iambic Therapeutics (IAM) raising $200M and $150M respectively. CTY priced at $18.00, opened at $23.00, and saw a 28% debut increase. IAM priced at $16.00 and is currently trading at $23.87. Anthropic (ANTP) is expected to IPO soon, but investors may seek lower valuation. Fed rate hikes and macro caution may impact IPO activity.
Iambic Therapeutics Inc., an AI-driven biotech firm backed by Nvidia, saw its shares rise 16% in its IPO debut, trading at $18.50 after raising $150 million. The company, which focuses on cancer drug discovery, now has a market value of $877 million. Proceeds will advance three early-stage drug candidates. Key investors include ARK Investment Management and Stanley Druckenmiller's Duquesne Family Office.
